Searched over 200M research papers
6 papers analyzed
Some studies suggest that stopping losartan can improve Parkinson's disease symptoms and alleviate losartan-induced acute pancreatitis, while other studies indicate it may lead to increased serum uric acid levels, potential kidney damage, and cardiovascular risks in certain patients.
20 papers analyzed
Losartan is a widely used angiotensin II receptor antagonist primarily prescribed for managing hypertension. It has additional benefits, such as reducing serum uric acid levels and providing renal protection in patients with type 2 diabetes and nephropathy . However, discontinuing losartan can have various effects on patients, which are important to understand for optimal patient care.
One notable case study highlights the exacerbation of Parkinsonism symptoms due to losartan. A 65-year-old patient with Parkinson's disease experienced significant worsening of bradykinesia, rigidity, and tremors after starting losartan. Upon discontinuation, the patient's symptoms improved markedly within 48 hours, suggesting a probable adverse effect of losartan on dopaminergic release. This case underscores the importance of monitoring neurological symptoms in patients with Parkinson's disease when prescribing losartan.
Losartan has been shown to lower serum uric acid levels by increasing urinary uric acid excretion. In a study involving hypertensive patients with hyperuricemia and gout, losartan significantly reduced serum uric acid levels, unlike irbesartan, another angiotensin II receptor antagonist. Therefore, stopping losartan may lead to an increase in serum uric acid levels, potentially exacerbating conditions like gout.
Losartan's role in blocking the angiotensin II type 1 receptor leads to increased plasma renin activity and angiotensin II levels. These effects are dose-related and diminish after discontinuation of the drug. Long-term blockade of the angiotensin II receptor by losartan results in modest increases in plasma renin activity and angiotensin II, which do not significantly affect its antihypertensive efficacy. Stopping losartan may normalize these biochemical markers, but the clinical implications need careful consideration.
In patients with type 2 diabetes and nephropathy, losartan has been shown to reduce the incidence of doubling serum creatinine levels and end-stage renal disease. It also lowers proteinuria and the rate of first hospitalization for heart failure. Discontinuing losartan in such patients could potentially reverse these benefits, leading to a progression of renal disease and increased cardiovascular risks.
Losartan is generally well-tolerated, but it can cause side effects such as dizziness, nausea, and headache. Serious adverse events like acute pancreatitis have also been reported, which resolved upon discontinuation of the drug . Therefore, stopping losartan may alleviate these adverse effects, but it requires careful management to avoid rebound hypertension or other complications.
Stopping losartan can have diverse effects depending on the patient's underlying conditions. While it may alleviate certain adverse effects, it can also lead to the worsening of conditions like hypertension, hyperuricemia, and renal disease. Clinicians must weigh the benefits and risks carefully and monitor patients closely during the transition to alternative therapies.
Most relevant research papers on this topic